do glp 1 drugs reduce inflammation The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury Anti-inflammatory properties of GLP-1 receptor

Thomas Seck Dr

The Discontinuation Hierarchy# Discontinuation rates due to adverse events provide a practical measure of tolerability that matters most to patients: Best tolerated: Ecnoglutide (~2%), Bioglutide (NR but minimal) Well tolerated: Semaglutide (4.3%), CT-388 (5.9%), Tirzepatide (4.3-7.1%) Moderate: Orforglipron (5.3-10.3%) Higher burden: Retatrutide (12.2-18.2%) Titration Matters# GI side effects are strongly concentrated during dose escalation

Mild comorbidities were allowed while severe diabetic complications or other diseases were excluded

1 Annual ferritin testing is reasonable for long-term GLP-1 RA users with fatigue, restless legs, or other suggestive symptoms

The most common etiologies of CKD were diabetic nephropathy/diabetic kidney disease (31%), glomerular disease (25%), hypertensive/renovascular disease (22%) and other/unknown (22%)